These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22335897)

  • 1. Characterization of TAE684 as a potent LRRK2 kinase inhibitor.
    Zhang J; Deng X; Choi HG; Alessi DR; Gray NS
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1864-9. PubMed ID: 22335897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
    Reith AD; Bamborough P; Jandu K; Andreotti D; Mensah L; Dossang P; Choi HG; Deng X; Zhang J; Alessi DR; Gray NS
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5625-9. PubMed ID: 22863203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
    Deng X; Dzamko N; Prescott A; Davies P; Liu Q; Yang Q; Lee JD; Patricelli MP; Nomanbhoy TK; Alessi DR; Gray NS
    Nat Chem Biol; 2011 Apr; 7(4):203-5. PubMed ID: 21378983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
    Dzamko N; Deak M; Hentati F; Reith AD; Prescott AR; Alessi DR; Nichols RJ
    Biochem J; 2010 Sep; 430(3):405-13. PubMed ID: 20659021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
    Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
    Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.
    Dzamko N; Inesta-Vaquera F; Zhang J; Xie C; Cai H; Arthur S; Tan L; Choi H; Gray N; Cohen P; Pedrioli P; Clark K; Alessi DR
    PLoS One; 2012; 7(6):e39132. PubMed ID: 22723946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
    Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K
    PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.
    Lobbestael E; Zhao J; Rudenko IN; Beylina A; Gao F; Wetter J; Beullens M; Bollen M; Cookson MR; Baekelandt V; Nichols RJ; Taymans JM
    Biochem J; 2013 Nov; 456(1):119-28. PubMed ID: 23937259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.
    Papkovskaia TD; Chau KY; Inesta-Vaquera F; Papkovsky DB; Healy DG; Nishio K; Staddon J; Duchen MR; Hardy J; Schapira AH; Cooper JM
    Hum Mol Genet; 2012 Oct; 21(19):4201-13. PubMed ID: 22736029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
    Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
    ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity.
    Nikonova EV; Xiong Y; Tanis KQ; Dawson VL; Vogel RL; Finney EM; Stone DJ; Reynolds IJ; Kern JT; Dawson TM
    Hum Mol Genet; 2012 Jan; 21(1):163-74. PubMed ID: 21972245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
    Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
    J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
    Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
    J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.